Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
Masaki IshidaKenji MorimotoTadaaki YamadaShinsuke ShiotsuYusuke ChiharaTakahiro YamadaOsamu HiranumaYoshie MorimotoMasahiro IwasakuShinsaku TokudaTakayuki TakedaKoichi TakayamaPublished in: Thoracic cancer (2021)
Our retrospective observations suggest that the group with longer PFS with chemoimmunotherapy might be expected to benefit from docetaxel plus ramucirumab treatment in second-line settings for patients with advanced NSCLC.